Optimizerx Corp income statement
In fiscal 2025, Optimizerx Corp reported revenue of $109m, up 18.8% on the year before, operating income of $11.7m (a 10.7% margin) and net income of $5.1m, or $0.27 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1 | 2 | 5 | 7 | 7 | 8 | 12 | 21 | 25 | 43 | 61 | 62 | 72 | 92 | 109 | 99 |
| Cost of revenue | — | — | — | — | — | — | — | — | 9 | 9 | 19 | 26 | 23 | 29 | 33 | 36 | 26 |
| Gross profit | — | — | 2 | 3 | 3 | 4 | 4 | 6 | 12 | 15 | 24 | 36 | 39 | 43 | 59 | 74 | 72 |
| Research and development | — | — | — | — | — | — | — | — | 0 | 2 | 0 | — | — | — | 0 | 0 | — |
| Selling, general and administrative | — | — | — | — | — | — | — | — | — | — | — | 28 | 33 | — | — | — | — |
| General and administrative | — | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −2 | −1 | −0 | −0 | −1 | −1 | −2 | −2 | 0 | −4 | −2 | 0 | −12 | −26 | −14 | 12 | 11 |
| Interest expense | −0 | 1 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | 1 | 6 | 5 | 5 |
| Income before tax | — | — | — | −0 | −1 | −1 | −2 | −2 | 0 | −4 | −2 | 0 | −11 | −25 | −19 | 7 | 7 |
| Income tax | — | — | — | 0 | 0 | 0 | — | — | — | −1 | — | — | — | −8 | 1 | 2 | 2 |
| Net income | −2 | −2 | −0 | −0 | −1 | −1 | −2 | −2 | 0 | −3 | −2 | 0 | −11 | −18 | −20 | 5 | 5 |
| Diluted EPS | — | — | — | −$0.06 | −$0.12 | — | −$0.05 | −$0.21 | $0.02 | −$0.23 | −$0.15 | $0.02 | −$0.64 | −$1.03 | −$1.10 | $0.27 | $0.24 |
| Diluted shares (average) | — | — | 6m | 7m | 8m | 8m | 10m | 10m | 12m | 13m | 15m | 18m | 18m | 17m | 18m | 19m | 19m |
| EBITDA | −2 | −1 | −0 | −0 | −1 | −0 | −1 | −2 | 0 | −2 | −0 | 2 | −10 | −24 | −9 | 16 | 15 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 32 | 22 | 29 | 26 | 32 | 20 | 21 |
| Cost of revenue | 8 | 10 | 9 | 11 | 9 | 8 | 5 | 5 |
| Gross profit | 13 | 22 | 13 | 19 | 18 | 24 | 15 | 16 |
| Research and development | — | — | 3 | 3 | — | — | 3 | 3 |
| Selling and marketing | — | — | 5 | 6 | — | — | 5 | 6 |
| General and administrative | 13 | — | 5 | 4 | 14 | — | 4 | 4 |
| Operating income | −9 | 4 | −2 | 3 | 2 | 9 | 0 | −0 |
| Interest expense | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 |
| Income before tax | −10 | 2 | −3 | 2 | 1 | 7 | −1 | −1 |
| Income tax | −1 | 2 | −1 | 0 | 0 | 2 | −0 | −0 |
| Net income | −9 | −0 | −2 | 2 | 1 | 5 | −0 | −1 |
| Diluted EPS | −$0.50 | $0.00 | −$0.12 | $0.08 | $0.04 | $0.26 | −$0.03 | −$0.04 |
| EBITDA | −7 | 5 | −1 | 4 | 3 | 10 | 1 | 1 |
Compare with peers
- Sophia Genetics SA income statement
- Carecloud, Inc. income statement
- American Well Corp income statement
- Definitive Healthcare Corp. income statement
- Health Catalyst, Inc. income statement
Head to head: OPRX vs SOPHCCLD vs OPRXAMWL vs OPRX
More: Health Care Technology stocks compared, Health Care sector, rankings of US companies